HOYA Vision Care and HOYA Surgical Optics Unite Efforts Against Myopia at the 41st ESCRS Congress

Vienna, Austria – 15th September 2023 – HOYA Vision Care, a leader in optical technology innovation, attended the 41^st European Society of Cataract & Refractive Surgeons (ESCRS) congress that took place on 8^th –12^th September 2023 in Vienna, Austria. The congress agenda for this year offered a wealth of sessions including main symposia, instructional courses, a full suite of wet lab courses, video sessions, posters, and oral presentations. 

This year, HOYA Vision Care collaborated against myopia together with HOYA Surgical Optics, delivering a shared corporate booth and hosted a symposium where Professor Kaymak presented on the topic of ‘Therapeutic Power of Multifocality in Myopic Children’. During the presentation, he shed light on the epidemiology, emphasizing the high prevalence of myopia. He delved into the risk factors of myopia and discussed the options for myopia management and evidence behind a combination treatment with MiYOSMART spectacle lens and atropine eye drops – a management choice that is gaining increasingly more interest and research in the myopia treatment space.^1-3  

HOYA Vision Care was also involved in the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) Subspecialty day, where the Global Head of Medical and Scientific Affairs, Dr. Natalia Vlasak, moderated the symposium titled “Myopia Management with MiYOSMART - New evidence and experiences from Europe”. During this symposium, Professor Bremond-Gignac presented new insights on myopia management in paediatric ophthalmology, with particular attention being brought to the new WSPOS 2023 myopia consensus statement.⁴ 

The presentation was followed by a talk from Professor Kaymak, who shared insights gained from a real-world 1-year study in Germany. Due to the lack of recognized guidance on treatment goals in myopia management, Professor Kaymak also provided his recommendation on when to start treatment and a new way to evaluate the treatment’s success in the short term.  

HOYA Vision Care is committed to sharing scientific knowledge and professional insights and provide innovative solutions to address the growing problem of myopia progression in children. By sharing new research and guidance the company will continue to help fight and control the growing problem of myopia around the world.   

Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of Myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S

For further information contact:

HOYA Vision Care PR

Susan Brown

susan@wearenomads.com

Follow HOYA Vision Care on Linkedin                                     

References:

1. 1. Huang Z, Chen XF, He T, Tang Y, Du CX. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep. 2022;12(1):22311.
2. 2. Kaymak H, Mattern AI, Graff B, Neller K, Langenbucher A, Seitz B, et al. Safety of DIMS Spectacle Lenses and Atropine as Combination Therapy for Myopia Progression. Klin Monbl Augenheilkd. 2022;239(10):1197-205.
3. 3. Nucci P, Lembo A, Schiavetti I, Shah R, Edgar DF, Evans BJW. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. PLoS One. 2023;18(2):e0281816.
4. 4. World Society of Paediatric Ophthalmology and Strabismus (WSPOS). Myopia Consensus Statement 2023. 2023.  Available from: https://www.wspos.org/swdcore/uploads/WSPOS-Myopia-Consensus-Statement-2023-1.pdf (Last accessed: 22/06/2023).